Jiangxi synergy pharmaceutical announced that the company recently received the 'Pharmaceutical Registration Certificate' for rivaroxaban tablets approved by the National Medical Products Administration. This pharmaceutical is an oral Xa indicator inhibitor used for the prevention and treatment of thrombotic events in adults and children. The product was originally developed by Bayer and was launched in Europe in 2008, and approved for sale domestically in 2009. Currently, the main holders of the market license for this pharmaceutical in the country include Nanjing Hicin Pharmaceutical Co., Ltd., Qilu Pharmaceutical Co., Ltd., and others, totaling 56 companies. In 2023, sales of rivaroxaban tablets in urban, county-level, and township-level public hospitals in our country amounted to approximately 1.74 billion yuan. The active pharmaceutical ingredient for this product is produced by the company, which helps to enhance market competitiveness.

- Latest
- Detail
同和药业:获得利伐沙班片药品注册证书
Jiangxi synergy pharmaceutical: obtained the registration certificate for rivaroxaban tablets.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Price
Log In for the Full List
Latest
23:36
Deutsche Bank: The trade war undermines the hawkish view of the Federal Reserve; a rate cut this year is no longer impossible.
DB-5.49%
23:36
KKR plans to issue a 3-year convertible stock to raise $1.5 billion.
KKR-7.82%
23:36
The S&P 500 Consumer Discretionary Sector fell by 2.7%, reaching its lowest level since November of last year.
Investment Course

Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.